[Cholestatic pruritus : new insights into pathophysiology and current treatment].
Pruritus is a common symptom of hepatobiliary disorders and may considerably diminish quality of life. Cholestatic pruritus exerts a circadian rhythm and is typically most severe in the evening hours and early at night. Itching is reported often to be most intense at the palms and the soles, but may also be generalized. The pathophysiological mechanisms of cholestatic pruritus have not been completely clarified. In the past, bile salts, histamine, progesterone metabolites and opioids have been discussed as potential causal substances; a correlation with itch intensity could never be proven. The enzyme autotaxin, which releases lysophosphatidic acid, has recently been identified as potential cholestatic pruritogen. Treatment aims to bind pruritogens in the gut lumen by resins such as cholestyramine, to modulate pruritogen metabolism by rifampicin and to influence central itch signaling by µ-opioid antagonists and selective serotonin re-uptake inhibitors. In cases of refractory pruritus experimental treatment options such as UV-therapy, extracorporeal albumin dialysis and nasobiliary drainage may be considered.
Medizinische Klinik, Gastroenterologie, Hepatologie, Pneumologie und Endokrinologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutschland. andreas.kremer@uk-erlangen.de
A E
AE
Kremer
R P J
RP
Oude Elferink
U
U
Beuers
D002779:Cholestasis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D006801:Humans; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D012293:Rifampin / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D009292:Narcotic Antagonists; D012702:Serotonin Antagonists; D012293:Rifampin